Association of Antibodies to Prevotella copri in Anti–Cyclic Citrullinated Peptide‐Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis
Authors' conclusion
Our findings support a potential etiologic role for P copri in both RA preclinical evolution and the subsequent pathogenesis of synovitis.
Study context
- Population
- Individuals at risk of developing rheumatoid arthritis (RA), who transitioned to RA, with early RA or established RA, and matched controls
- Comparison
- At-risk, transitioned, early RA and established RA participants vs matched controls
- Outcome
- Serum IgA and IgG antibodies to a 27-kd P copri protein (anti-Pc-p27)
Methodological detailsmatched controls, stratified by RA-related autoantibody status
- Matched controls
- Stratified by RA-related autoantibody status
Main finding
As reported in the abstract
- RA: significantly higher immunoglobulin A (IgA) anti-P copri (anti-Pc)-p27 levels vs matched controls
- RA: trend toward higher IgG anti-Pc-p27 levels vs matched controls
Observational data: associations, not effects.
Further findings
Anti-Pc-p27 levels, early vs established RA
- Early RA: median IgG anti-Pc-p27 levels overall higher
- Established RA: median IgA anti-Pc-p27 levels statistically significantly higher vs matched controls
Anti-Pc-p27 levels by autoantibody status
- At-risk anti-cyclic citrullinated peptide (anti-CCP)+, but not rheumatoid factor (RF)+: trend toward increased IgG anti-Pc-p27
- RA seropositive for both CCP and RF: significantly increased IgA and trend toward higher IgG anti-Pc-p27 vs matched controls
Original publication
Association of Antibodies to Prevotella copri in Anti–Cyclic Citrullinated Peptide‐Positive Individuals At Risk of Developing Rheumatoid Arthritis and in Patients With Early or Established Rheumatoid Arthritis. Arthritis Rheumatol. Published 22 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →